Moderna and Merck Vaccine Cuts Melanoma Recurrence Risk by 42%
The combination also cut the risk of distant metastasis by 38% in a late-stage trial of more than 1,100 patients.
- On Thursday, Moderna and Merck announced their mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence or death risk by 42% and disease spread by 38% in a large clinical trial.
- In a Phase 3 trial of more than 1,100 patients, the vaccine intismeran targeted up to 34 neoantigens to train the immune system, marking an advance in personalized cancer treatment.
- Among those receiving the vaccine plus Keytruda, 82.2% remained cancer-free after two years versus 70% for Keytruda alone. Dr. Hussein Tawbi of the University of Texas MD Anderson Cancer Center said the results were "highly statistically significant."
- Following the early leak of trial results, Moderna shares fell over 20% on Thursday, while Merck shares declined around 1%, as analysts described the market response as a "sell-the-news reaction is playing out."
- Merck and Moderna are conducting additional studies in lung, bladder, and kidney cancer, with RBC analyst Huynh noting interim kidney tumor results could arrive later this year or in early 2027.
30 Articles
30 Articles
Associated Press News
A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return.
According to one study, the mRNA cancer vaccine developed by US companies Moderna and Merck significantly reduces the risk of death and relapse in black skin cancer (melanoma) in combination with tried-and-tested immunotherapy. Treatment reduces this risk by 42 percent, as data show.
Moderna and Merck said Thursday that their mRNA-based cancer vaccine, when combined with Merck’s widely used immunotherapy, reduced the risk of death or recurrence of melanoma by 42 percent in a large clinical trial. The result could pave the way for a new era of personalized treatments. Data from the Phase 3 study, which included more than 1,100 patients, also showed that the combination reduced the risk of the cancer spreading by 38 percent.
The Independent
The Independent (US)mRNA cancer vaccine slashes melanoma death or recurrence risk by 42%
Moderna CEO Stephane Bancel said that the findings herald a new chapter in treating cancer
Experimental mRNA vaccine cuts risk melanoma returns by 42%
By Meg Tirrell, CNN (CNN) — When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated. And that was before its makers had even disclosed just how well the therapy worked.Now they have.
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
